Notably, several Rb-deficient squamous cancer cell lines are resistant to standard therapies, including cisplatin and radiotherapy, suggesting the potential effectiveness of this combination strategy in treating recurrent and therapy-resistant cancers, a critical area of unmet need. Here, RB1 is linked to cancer.